Abstract | INTRODUCTION:
Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder with a high prevalence. Besides efficacy, the safety of each drugs used to treat GI disorders is an important issue in the drug development process. AREAS COVERED: This article reviews all Phase I to IV clinical trials or case reports with results related to the safety of novel GI drugs. The drugs are currently approved or under evaluation for approval. EXPERT OPINION:
|
Authors | Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 13
Issue 5
Pg. 625-38
(May 2014)
ISSN: 1744-764X [Electronic] England |
PMID | 24669839
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
|
Topics |
- Gastrointestinal Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
- Irritable Bowel Syndrome
(complications, drug therapy)
- Randomized Controlled Trials as Topic
|